Biomerica (NASDAQ:BMRA – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.83, Zacks reports. Biomerica had a negative net margin of 84.79% and a negative return on equity of 97.19%.
Biomerica Trading Up 2.2%
BMRA stock traded up $0.04 during midday trading on Thursday, hitting $1.84. The company’s stock had a trading volume of 13,846 shares, compared to its average volume of 36,222. The company has a market cap of $5.69 million, a PE ratio of -1.45 and a beta of 0.38. Biomerica has a 12 month low of $1.45 and a 12 month high of $3.21. The firm’s 50-day moving average is $2.04 and its 200-day moving average is $2.01.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised shares of Biomerica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. One analyst has rated the stock with a Sell rating. According to MarketBeat, the stock currently has a consensus rating of “Sell” and an average price target of $9.00.
Check Out Our Latest Stock Analysis on Biomerica
Insider Buying and Selling at Biomerica
In other Biomerica news, Director M. Huff Gary bought 31,250 shares of Biomerica stock in a transaction on Thursday, August 20th. The stock was acquired at an average price of $1.60 per share, with a total value of $50,000.00. Following the acquisition, the director owned 51,250 shares in the company, valued at approximately $82,000. This trade represents a 156.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Vice Chairman Allen Barbieri bought 20,000 shares of Biomerica stock in a transaction on Wednesday, August 26th. The stock was acquired at an average cost of $1.60 per share, with a total value of $32,000.00. Following the acquisition, the insider owned 73,542 shares in the company, valued at approximately $117,667.20. This represents a 37.35% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 92,500 shares of company stock worth $148,000. Insiders own 18.00% of the company’s stock.
Biomerica Company Profile
Biomerica, Inc is a medical diagnostics company that develops and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. The company focuses on tests and related solutions intended to support more personalized treatment decisions.
Biomerica’s best-known product platform is inFoods, which uses blood-based testing to identify foods that may contribute to symptoms associated with gastrointestinal disorders. The company has emphasized inFoods IBS, a diagnostic-guided dietary management solution for people with irritable bowel syndrome, pairing test results with individualized food recommendations.
Biomerica also has developed and marketed diagnostic products for conditions including Helicobacter pylori infection, allergies and respiratory illnesses.
Read More
- Five stocks we like better than Biomerica
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.
